Theravance Biopharma (TBPH) Capital Expenditures (2013 - 2025)
Theravance Biopharma (TBPH) reported Capital Expenditures of $8000.0 for Q4 2025, down 95.79% year-over-year from $190000.0 in Q4 2024, and down 95.79% quarter-over-quarter from $190000.0 in Q4 2024.
Theravance Biopharma (TBPH) Capital Expenditures (2013 - 2025) Analysis & Trends
Theravance Biopharma (TBPH) has 13 years of Capital Expenditures data on file, last reported at $8000.0 in Q4 2025.
- Capital Expenditures for Q4 2025 came in at $8000.0, down 95.79% year-over-year; the trailing twelve-month figure through Dec 2025 was $213000.0 (down 35.84% YoY), and the FY2025 annual result was $42000.0, down 87.35% from the prior year.
- Capital Expenditures fell to $8000.0 in Q4 2025 per TBPH's latest filing, from $190000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $1.8 million in Q1 2021 and troughed at -$57000.0 in Q3 2022.
- A 5-year average of $400352.9 and a median of $190000.0 in 2024 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2022 and 2023: Capital Expenditures plunged 105.49% in 2022, then surged 653.98% in 2023.
- A 5-year view of Capital Expenditures shows it stood at $444000.0 in 2021, then plunged by 40.09% to $266000.0 in 2022, then surged by 154.51% to $677000.0 in 2023, then slumped by 71.94% to $190000.0 in 2024, then slumped by 95.79% to $8000.0 in 2025.
- Business Quant data shows TBPH's Capital Expenditures at $8000.0 in Q4 2025, $190000.0 in Q4 2024, and $15000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -63,220.27 |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8,000.00 |
| Dec 31, 2025 | 8,000.00 |
| Dec 31, 2024 | 190,000.00 |
| Dec 31, 2024 | 190,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Jun 30, 2024 | 36,000.00 |
| Jun 30, 2024 | 36,000.00 |
| Mar 31, 2024 | 91,000.00 |
| Mar 31, 2024 | 91,000.00 |
| Dec 31, 2023 | 677,000.00 |
| Dec 31, 2023 | 677,000.00 |
| Sep 30, 2023 | 21,000.00 |
| Sep 30, 2023 | 21,000.00 |
| Jun 30, 2023 | 852,000.00 |
| Jun 30, 2023 | 852,000.00 |
| Mar 31, 2023 | 938,000.00 |
| Mar 31, 2023 | 938,000.00 |
| Dec 31, 2022 | 266,000.00 |
| Dec 31, 2022 | 266,000.00 |